|Articles|May 9, 2017

WIRB-Copernicus Acquires Again

WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization.

WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization. This acquisition provides WCG’s clients with a more comprehensive and integrated suite of study start-up solutions.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

WIRB-Copernicus Acquires Again

Related Content

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

Trending on Applied Clinical Trials Online

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion